[go: up one dir, main page]

PE20181070A1 - Moleculas bifuncionales que contienen peg para uso en la inhibicion de cataratas y presbicia - Google Patents

Moleculas bifuncionales que contienen peg para uso en la inhibicion de cataratas y presbicia

Info

Publication number
PE20181070A1
PE20181070A1 PE2018000767A PE2018000767A PE20181070A1 PE 20181070 A1 PE20181070 A1 PE 20181070A1 PE 2018000767 A PE2018000767 A PE 2018000767A PE 2018000767 A PE2018000767 A PE 2018000767A PE 20181070 A1 PE20181070 A1 PE 20181070A1
Authority
PE
Peru
Prior art keywords
presbycia
cataract
inhibition
molecules containing
containing peg
Prior art date
Application number
PE2018000767A
Other languages
English (en)
Inventor
Murugappan Muthukumar
Original Assignee
Univ Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts filed Critical Univ Massachusetts
Publication of PE20181070A1 publication Critical patent/PE20181070A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00—Optical parts
    • G02C7/02—Lenses; Lens systems ; Methods of designing lenses
    • G02C7/04—Contact lenses for the eyes

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Eyeglasses (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)

Abstract

SE REFIERE A UNA COMPOSICION OFTALMICA QUE COMPRENDE I) UNA MOLECULA BIFUNCIONAL QUE COMPRENDE UNA AMINA, SUCCINIMIDA, ACIDO CARBOXILICO, ISOCIANATO, ISOTIOCIANATO, ENTRE OTROS, SIENDO PREFERIDOS LOS COMPUESTOS DE FORMULA (i) Y (ii); UNIDA COVALENTEMENTE A II) UNA CERDA MOLECULAR QUE ES UN POLIETILENGLICOL QUE TIENE DE 1 A 3 GRUPOS OXIETILENO, UN ALCOXI-POLIETILENGLICOL QUE TIENE DE 1 A 3 GRUPOS ALCOXIETILENO, O UN ARILOXIPOLIETILENGLICOL. DICHA COMPOSICION OFTALMICA ES DE LIBERACION SOSTENIDA QUE ADEMAS INCLUYE UN AGENTE TAMPONANTE, UN AGENTE ISOTONICO, UN SOLUBILIZANTE, UN ANTIBIOTICO, ENTRE OTROS, SIENDO UTIL PARA INHIBIR O REVERTIR LA PROGRESION DE LA FORMACION DE CATARATAS, PRESBICIA O DEGENERACION ASOCIADA A LA EDAD DEL CRISTALINO EN UN OJO
PE2018000767A 2015-11-13 2016-11-11 Moleculas bifuncionales que contienen peg para uso en la inhibicion de cataratas y presbicia PE20181070A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562254863P 2015-11-13 2015-11-13

Publications (1)

Publication Number Publication Date
PE20181070A1 true PE20181070A1 (es) 2018-07-04

Family

ID=57421950

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000767A PE20181070A1 (es) 2015-11-13 2016-11-11 Moleculas bifuncionales que contienen peg para uso en la inhibicion de cataratas y presbicia

Country Status (18)

Country Link
US (1) US10736863B2 (es)
EP (1) EP3373921B1 (es)
JP (1) JP6794444B2 (es)
KR (1) KR102696354B1 (es)
CN (1) CN108348494A (es)
AU (1) AU2016354479B2 (es)
CA (1) CA3004585A1 (es)
CL (1) CL2018001282A1 (es)
CR (1) CR20180294A (es)
EA (1) EA035402B1 (es)
ES (1) ES2745291T3 (es)
IL (1) IL259027B (es)
MX (1) MX376641B (es)
PE (1) PE20181070A1 (es)
SA (1) SA518391553B1 (es)
SG (1) SG11201803606XA (es)
WO (1) WO2017083619A1 (es)
ZA (1) ZA201802978B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102198622B1 (ko) 2013-03-14 2021-01-05 유니버시티 오브 매사추세츠 백내장 및 노안을 억제하는 방법
PE20181070A1 (es) 2015-11-13 2018-07-04 Univ Massachusetts Moleculas bifuncionales que contienen peg para uso en la inhibicion de cataratas y presbicia
US10220012B2 (en) * 2016-06-03 2019-03-05 Joerg H. KRUMEICH Solution for ophthalmology
TWI798452B (zh) * 2019-06-17 2023-04-11 晶碩光學股份有限公司 隱形眼鏡產品
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351826A (en) 1980-02-29 1982-09-28 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using acrylamides
US4526789A (en) 1980-02-29 1985-07-02 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation
US4665089A (en) 1985-03-21 1987-05-12 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using protein modification reagents
US4620979A (en) 1985-08-02 1986-11-04 Schachar Ronald A Ophthalmological irrigating solution containing ascorbate
US4771036A (en) 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
CA1269327A (en) 1986-04-24 1990-05-22 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using protein modification reagents
US5055291A (en) 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4808182A (en) 1986-11-26 1989-02-28 Nestle, S.A. Deswelled, hydrogel intraocular lenses
US5338545A (en) 1987-06-04 1994-08-16 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
US5091421A (en) 1987-06-04 1992-02-25 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors
US5614587A (en) 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
DE3906311A1 (de) 1989-02-28 1990-08-30 Adatomed Pharma & Med Behandlungsystem zur verhinderung von nachstarbildung nach einer kataraktoperation
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
ATE138914T1 (de) 1990-12-10 1996-06-15 Bio Physio Pharmaceutical Rese Indeno-d-pyrimidonverbindungen zur verwendung in der medizin
WO1993000109A1 (en) 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
HUT71250A (en) 1992-05-20 1995-11-28 Senju Pharma Co Remedy for cataract and production thereof
US5375611A (en) 1993-01-26 1994-12-27 Pharmacia Ab Method for preventing secondary cataract
CN1045383C (zh) 1993-04-07 1999-10-06 王慧康 用于治疗老年性白内障的药物组合物
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
JPH09505057A (ja) 1993-11-19 1997-05-20 ザ・ユニバーシティ・オブ・シドニー 白内障を予防または制御するための方法
US5516534A (en) 1993-11-26 1996-05-14 Rensselaer Polytechnic Institute Composition and method for reducing structural defects
US5591773A (en) 1994-03-14 1997-01-07 The Trustees Of Columbia University In The City Of New York Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters
DE69530553T2 (de) 1994-05-13 2004-03-25 KURARAY CO., LTD, Kurashiki Medizinisches polymergel
EP0733918B1 (en) 1995-03-24 2003-07-30 Ocular Research of Boston, Inc. Hydrogel lens pre-coated with lipid layer
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JP3599848B2 (ja) 1995-09-11 2004-12-08 株式会社メニコン 含水性軟質眼用レンズ用材料、それからなる含水性軟質眼用レンズ用成形体、ならびにそれからなる含水性軟質眼用レンズおよびその製法
EP0781777A1 (en) 1995-12-28 1997-07-02 Menicon Co., Ltd. Silicon-containing compound and ocular lens material
DE69714663T2 (de) 1996-06-28 2003-04-10 Ube Industries, Ltd. Verfahren zur Herstellung von Polybutadien
US5817630A (en) 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
JPH10339857A (ja) 1997-06-05 1998-12-22 Menicon Co Ltd 薬剤徐放性コンタクトレンズの製法およびそれによってえられた薬剤徐放性コンタクトレンズ
US6015787A (en) 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
US6291466B1 (en) 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
EP1149909A1 (en) 2000-04-28 2001-10-31 Boehringer Mannheim Gmbh Methods for regulating protein conformation using molecular chaperones
US6103756A (en) 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
CA2389917A1 (en) 1999-11-04 2001-05-10 Kazunori Kataoka A polymer micelle as monolayer or layer-laminated surface
US6835394B1 (en) 1999-12-14 2004-12-28 The Trustees Of The University Of Pennsylvania Polymersomes and related encapsulating membranes
US7977385B2 (en) 2000-03-02 2011-07-12 Numoda Biotechnologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
EP1284743A2 (en) 2000-05-31 2003-02-26 Cerus Corporation Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity
DK1341813T3 (da) 2000-12-15 2007-01-15 Sigma Tau Ind Farmaceuti Anvendelse af L-carnitin som stabiliseringsmiddel af proteiner
US6958224B2 (en) 2001-03-28 2005-10-25 Council Of Scientific And Industrial Research Chimeric protein α BNAC crystallin with extraordinarily high chaperone-like activity and a method related to the use thereof
US20030020870A1 (en) 2001-06-27 2003-01-30 Zms, Llc Biomedical molding materials from semi-solid precursors
JP4838968B2 (ja) * 2001-09-28 2011-12-14 参天製薬株式会社 薬物−ポリエチレングリコール結合体を含有する眼組織内注入剤
WO2003028765A1 (en) * 2001-09-28 2003-04-10 Santen Pharmaceutical Co., Ltd. Injections for eye tissue containing drug bound to polyethylene glycol
US20050260259A1 (en) 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
WO2003086305A2 (en) 2002-04-10 2003-10-23 The Regents Of The University Of California Biodegradable peg-based polymer formulations in ocular applications
US6924154B2 (en) 2002-08-20 2005-08-02 Quest Diagnostics Investments Incorporated Hydrophilic chemilumescent acridinium labeling reagents
JP2004161731A (ja) 2002-09-25 2004-06-10 Nof Corp 生体関連物質用固定化剤
HUE027661T2 (en) 2003-03-05 2016-10-28 Halozyme Inc Soluble Hyaluronidase Glycoprotein (sHASEGP), Processes, Applications, and Pharmaceuticals Containing It
CN1621091A (zh) 2003-11-28 2005-06-01 付经国 聚乙二醇化轮状病毒体肠靶向制剂及其合成方法
EP1711510A4 (en) 2004-02-05 2008-11-26 Intradigm Corp RNAI THERAPEUTIC FOR THE TREATMENT OF EYE DISEASES WITH VASCULAR REPRODUCTION
US7887847B2 (en) 2004-05-08 2011-02-15 Paul Jr Edward L Nutritional supplement for treatment of ocular diseases
WO2005117987A1 (en) 2004-06-01 2005-12-15 Glazier Alan N Antibody conjugates targeting to ocular proteins
US6945971B1 (en) 2004-07-19 2005-09-20 Gwon Arlene E Controlled ocular lens regeneration
EP2626368B1 (en) 2004-07-19 2016-12-21 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
AU2005304874A1 (en) 2004-11-04 2006-05-18 University Of Washington Compositions and methods for treatment of protein misfolding and protein aggregation diseases
US7741311B2 (en) 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
CN1660920A (zh) 2005-02-01 2005-08-31 华东理工大学 末端连接ω－氨基酸的聚乙二醇酸或活性酯及制法和应用
US20060252107A1 (en) 2005-02-22 2006-11-09 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
DE102005041570A1 (de) 2005-09-01 2007-03-22 Celares Gmbh Hoch verzweigte Reagenzien zur Modifaktion von Biopharmazeutika, deren Herstellung und Anwendung
US7832875B2 (en) 2005-09-29 2010-11-16 Virtek Vision International Inc. Modulated diode pumped microchip laser projector
US20080094573A1 (en) 2006-04-04 2008-04-24 Vermette Patrick Surface-modified materials, such as contact lenses, methods and kits for their preparation, and uses thereof
US20070275098A1 (en) 2006-05-19 2007-11-29 T.R.P. Company, Inc, A Nevada Corporation Formulation and methodology for the treatment for eye impairment symptoms
WO2008145721A2 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
WO2009029991A1 (en) 2007-09-07 2009-03-12 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity
CN101903045B (zh) 2007-10-19 2013-03-13 株式会社·R-技术上野 用于治疗白内障的药物组合物
KR20100000203A (ko) 2008-06-24 2010-01-06 인하대학교 산학협력단 금나노입자를 이용한 표적지향형 항암약물전달체
RU2011103173A (ru) 2008-06-30 2012-08-10 Джонсон Энд Джонсон Вижн Кэа, Инк. (Us) Способы и офтальмологические изделия для лечения аллергических заболеваний глаз
WO2010007626A1 (en) * 2008-07-14 2010-01-21 Biocon Limited A method of synthesizing a substantially monodispersed mixture of oligomers
WO2010065024A1 (en) 2008-12-05 2010-06-10 Kador Peter F Topical treatment of cataracts in dogs
WO2010130638A1 (en) 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
JP2013513622A (ja) * 2009-12-14 2013-04-22 ユニバーシティ オブ マサチューセッツ 白内障及び老眼を阻害する方法
WO2011133566A2 (en) 2010-04-19 2011-10-27 University Of Louisville Research Foundation, Inc. Repairing bruch's membrane with hydrogels
CA2930801C (en) * 2010-11-05 2019-05-28 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CN102172410B (zh) 2011-01-14 2013-08-07 华南理工大学 用于癌症诊断与治疗的靶向纳米粒传输系统的构建方法
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
EP2691973B1 (en) 2011-03-31 2019-05-08 DH Technologies Development Pte. Ltd. Composition, method, and kit for calibrating a mass spectrometer
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
EP2718292B1 (en) * 2011-06-03 2018-03-14 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
US9441024B2 (en) 2011-09-04 2016-09-13 Glytech, Inc. Glycosylated polypeptide and drug composition containing said polypeptide
CN104010626A (zh) 2011-10-12 2014-08-27 阿森迪斯药物眼科部股份有限公司 眼病症的预防和治疗
CN102579353B (zh) 2012-03-30 2013-12-04 吉林大学 叶酸靶向的抗癌药物peg修饰的脂质体及制备方法
CN110101708A (zh) * 2012-07-17 2019-08-09 密执安大学评议会 治疗白内障的非手术方法
DK2906246T3 (da) 2012-10-11 2023-09-04 Ascendis Pharma Ophthalmology Div A/S VEGF-neutraliserende prodrugs omfattende ranibizumab til behandling af okulære tilstande, der er kendetegnet ved okulær neovaskularisering
WO2014071132A1 (en) 2012-11-01 2014-05-08 The Johns Hopkins University Contact lens surface modification with hyaluronic acid (ha) binding peptide for ha accumulation and retention
KR102198622B1 (ko) 2013-03-14 2021-01-05 유니버시티 오브 매사추세츠 백내장 및 노안을 억제하는 방법
WO2014171842A1 (en) * 2013-04-19 2014-10-23 Living Cell Technologies New Zealand Limited Biocompatible encapsulation system
US10835608B2 (en) 2013-12-05 2020-11-17 Nian Wu Polymer-carbohydrate conjugates for drug delivery technology
PE20181070A1 (es) 2015-11-13 2018-07-04 Univ Massachusetts Moleculas bifuncionales que contienen peg para uso en la inhibicion de cataratas y presbicia

Also Published As

Publication number Publication date
US10736863B2 (en) 2020-08-11
IL259027A (en) 2018-06-28
MX376641B (es) 2025-03-07
IL259027B (en) 2021-05-31
MX2018005903A (es) 2019-04-04
JP2018536659A (ja) 2018-12-13
SG11201803606XA (en) 2018-05-30
KR102696354B1 (ko) 2024-08-19
CR20180294A (es) 2018-08-10
EA201891161A1 (ru) 2018-10-31
AU2016354479A1 (en) 2018-05-24
CN108348494A (zh) 2018-07-31
US20170135972A1 (en) 2017-05-18
CA3004585A1 (en) 2017-05-18
WO2017083619A1 (en) 2017-05-18
ZA201802978B (en) 2019-07-31
ES2745291T3 (es) 2020-02-28
SA518391553B1 (ar) 2021-03-01
EP3373921B1 (en) 2019-08-28
EP3373921A1 (en) 2018-09-19
CL2018001282A1 (es) 2018-11-16
BR112018009582A2 (pt) 2018-11-06
EA035402B1 (ru) 2020-06-08
AU2016354479B2 (en) 2021-10-07
JP6794444B2 (ja) 2020-12-02
KR20180083378A (ko) 2018-07-20

Similar Documents

Publication Publication Date Title
PE20181070A1 (es) Moleculas bifuncionales que contienen peg para uso en la inhibicion de cataratas y presbicia
EP3506886A4 (en) HIGH-CONCENTRATED LOW VISCOUS MASP-2-INHIBITORY ANTIBODY FORMULATIONS, KITS AND METHODS
CO7121325A2 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
CY1125030T1 (el) Ενωσεις τρικυκλικης βενζοξαβορολης και χρησεις αυτων
EA202090868A1 (ru) Составы
UY38403A (es) Moduladores de la alfa-1 antitripsina
CR20150436A (es) Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo
BR112014032910A2 (pt) solfactants de éter de glicerina etoxilado
UY37098A (es) Moduladores de ror-gamma
CL2019001993A1 (es) Inhibidores selectivos de jak1.
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
AR080507A1 (es) Composiciones detergentes liquidas que comprenden un gelificante diamido y los procesos para elaborarlas
MX381639B (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
CY1113386T1 (el) Αναστολεις πρωτεασωματος
CR20160419A (es) Nuevos compuestos biciclicos
MX2019004690A (es) Constructos de anticuerpos.
BR112016009071A8 (pt) Composição cosmética em forma de nanofibras, método de produção de composição e uso
MX2021000189A (es) Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias.
CL2017000014A1 (es) Derivados de isondolina para su uso en el tratamiento de una infección viral
EP3752486A4 (en) Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems
SA522431498B1 (ar) مشتقات 3، 6-داي أمينو-بيريدازين-3-يل، تركيبات صيدلية تحتوي عليها واستخدامها في صورة عوامل مساعدة على تلاشي الخلايا
CY1122287T1 (el) Ενωσεις χρησιμες για την αναστολη toy ror-γαμμα-τ
MX388814B (es) Formulaciones de oxido de polialquileno-asparaginasa y metodos de preparacion y uso del mismo.
PE20171432A1 (es) Compuestos de benzoxaborol y uso de los mismos